{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T10:48:49Z","timestamp":1789296529884,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["ZYJGKX202404"],"award-info":[{"award-number":["ZYJGKX202404"]}],"id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["CI2021A05502"],"award-info":[{"award-number":["CI2021A05502"]}],"id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phymed.2025.157502","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:08:39Z","timestamp":1761869319000},"page":"157502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Shengbai oral solution for chemotherapy-induced neutropenia and symptom management in non-small cell lung cancer: A multicenter, randomized, open-label trial"],"prefix":"10.1016","volume":"148","author":[{"given":"Jiayue","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-3809","authenticated-orcid":false,"given":"Qiuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchang","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoli","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2025.157502_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2025.157502_bib0003","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4429","article-title":"Efficacy of Plinabulin vs Pegfilgrastim for prevention of chemotherapy-induced neutropenia in adults with non-small cell lung cancer: a phase 2 randomized clinical trial","volume":"6","author":"Blayney","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0005","first-page":"529","article-title":"Efficacy of Shengbai Oral Solution in treating leukopenia after chemotherapy in non-small cell lung cancer: a clinical observation of 58 cases","volume":"20","author":"Chen","year":"2013","journal-title":"Chin. J. Tradit. Chin. Med. Pharmacy"},{"key":"10.1016\/j.phymed.2025.157502_bib0006","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2010.33.4425","article-title":"Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center","volume":"29","author":"Cleeland","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cncr.27744","article-title":"Recommendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.phymed.2025.157502_bib0008","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2009.0006","article-title":"Myeloid growth factors","volume":"7","author":"Crawford","year":"2009","journal-title":"J. Natl. Compreh. Cancer Netw."},{"key":"10.1016\/j.phymed.2025.157502_bib0009","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0010","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2005.03.045","article-title":"Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature","volume":"23","author":"D'addario","year":"2005","journal-title":"J. Clinic. Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0011","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tmrv.2008.05.005","article-title":"Granulocyte colony-stimulating factor administration: adverse events","volume":"22","author":"D'souza","year":"2008","journal-title":"Transfus Med. Rev."},{"key":"10.1016\/j.phymed.2025.157502_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00003495-200868060-00002","article-title":"Bevacizumab in non-small cell lung cancer","volume":"68","author":"Di Costanzo","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.phymed.2025.157502_bib0013","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/01635581.2024.2383336","article-title":"Cancer-related therapeutic potential of epimedium and its extracts","volume":"76","author":"Ding","year":"2024","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.phymed.2025.157502_bib0014","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.phymed.2025.157502_bib0015","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/JTO.0b013e3181a52964","article-title":"XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy","volume":"4","author":"Gatzemeier","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0016","first-page":"763","article-title":"Shengxuebao Heji in treating leukopenia after chemotherapy in patients with non - small cell lung cancer: a multi - centered, randomized, double - blind controlled trial of 210 cases","volume":"58","author":"He","year":"2017","journal-title":"J. Trad. Chin. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0017","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0018","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phymed.2025.157502_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103193","article-title":"Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: a systematic review","volume":"157","author":"Lapidari","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phymed.2025.157502_bib0020","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgx010","article-title":"Validation and application of the MD Anderson symptom Inventory for Traditional Chinese Medicine (MDASI-TCM)","volume":"2017","author":"Li","year":"2017","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.phymed.2025.157502_bib0022","series-title":"Clinical Practice Guidelines of Chinese Medicine in Oncology","author":"Lin","year":"2016"},{"key":"10.1016\/j.phymed.2025.157502_bib0023","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11684-011-0137-7","article-title":"Developments in cancer prevention and treatment using traditional Chinese medicine","volume":"5","author":"Lin","year":"2011","journal-title":"Front. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/PPO.0000000000000404","article-title":"Evaluation of traditional Chinese medicine herbs in oncology clinical trials","volume":"25","author":"Liu","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.phymed.2025.157502_bib0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1759-7714.12270","article-title":"Traditional Chinese medicine and cancer: history, present situation, and development","volume":"6","author":"Liu","year":"2015","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.phymed.2025.157502_bib0026","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s11136-024-03778-x","article-title":"Symptom clusters and impact on quality of life in lung cancer patients undergoing chemotherapy","volume":"33","author":"Luo","year":"2024","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.phymed.2025.157502_bib0027","first-page":"2916","article-title":"Multi - centers, randomized controlled clinical study on Qijiaoshengbai capsules in prevention and treatment of leukopenia (Qi and Blood Deficiency Syndrome) caused by chemotherapy of lung cancer","volume":"16","author":"Lv","year":"2021","journal-title":"World J. Trad. Chin. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JOP.18.00750","article-title":"Febrile Neutropenia: an ounce of prevention or a pound of cure","volume":"15","author":"Lyman","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.phymed.2025.157502_bib0029","first-page":"144","article-title":"Integrative oncology: addressing the global challenges of cancer prevention and treatment","volume":"72","author":"Mao","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phymed.2025.157502_bib0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/13696998.2017.1358173","article-title":"Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia","volume":"20","author":"Mcbride","year":"2017","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.phymed.2025.157502_bib0031","first-page":"32","article-title":"Clinical and experimental study on Shengbai Bao in the treatment of leukopenia induced by radiotherapy and chemotherapy","author":"Shao","year":"1996","journal-title":"Henan J. Tradit. Chin. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0032","first-page":"207","article-title":"Treatment of chemoradiotherapy-induced leukopenia with Shengbai Oral Liquid","author":"Shao Y Y","year":"2000","journal-title":"J. Tradit. Chin. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0033","series-title":"Fundamentals of Chinese Medicine","author":"Sun","year":"2014"},{"key":"10.1016\/j.phymed.2025.157502_bib0034","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1705722","article-title":"Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project","volume":"40","author":"Tigue","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.phymed.2025.157502_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health","year":"2006","journal-title":"Health Qual. Life Outcom."},{"key":"10.1016\/j.phymed.2025.157502_bib0035","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J. Clinic. Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0036","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12957-024-03594-0","article-title":"Symptom burden and clusters during chemotherapy in patients with lung cancer","volume":"22","author":"Wang","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.phymed.2025.157502_bib0037","first-page":"1931","article-title":"Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy","volume":"25","author":"Wong","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.phymed.2025.157502_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.120351","article-title":"System pharmacology reveals the mechanism of action of Shengbai Oral Liquid alleviates chemotherapy-induced leukopenia by interfering the Pro-Platelet Basic Protein: integrated network study of multi-omics","author":"Wu","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.phymed.2025.157502_bib0039","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.21037\/apm-19-531","article-title":"Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer","volume":"9","author":"Zeng","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.phymed.2025.157502_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/jssc.202300350","article-title":"Integrated strategy facilitates rapid in-depth chemome characterization of traditional Chinese medicine prescriptions: Shengbai oral liquid as a case","volume":"46","author":"Zhang","year":"2023","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.phymed.2025.157502_bib0042","first-page":"131","article-title":"Efficacy of Shengbai mixture in treating myelosuppression after chemotherapy in lung cancer","volume":"24","author":"Zhou","year":"2018","journal-title":"J. Integr. Tradit. Western Surg."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325011390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325011390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:47:34Z","timestamp":1777592854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711325011390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":39,"alternative-id":["S0944711325011390"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157502","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shengbai oral solution for chemotherapy-induced neutropenia and symptom management in non-small cell lung cancer: A multicenter, randomized, open-label trial","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157502"}}